Ended Therapeutic confirmatory (Phase III) Obesity

A research study to see how well different doses of CagriSema help people with excess body weight lose weight

EU CTIS ID: 2023-509273-24-00

What this study is testing

To confirm superiority on body weight reduction of CagriSema 00 mg/00 mg and CagriSema 00 mg/00 mg versus placebo as an adjunct to reduced-calorie diet and increased physical activity in participants with overweight or obesity.

  • Therapeutic confirmatory (Phase III)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

  • History of at least one self-reported unsuccessful dietary effort to lose body weight
  • a) BMI ≥30.0 kg/m2a or b) BMI ≥27.0 kg/m2a with the presence of at least one obesity-related complication including, but not limited to hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease

You likely can't join if

  • HbA1c ≥6.5% (48 mmol/mol) as measured by the central laboratory at screening
  • History of type 1 or type 2 diabetes

The study team makes the final eligibility decision.

Where it's taking place

  • Canada
  • United Kingdom
  • United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Canada; United Kingdom; United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.